Apatinib Combined with Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma Followed by Apatinib Maintenance Therapy (AIT-NB-01): A Multicentre, Single-Arm, Phase 1/2 Trial
Background: Relapsed or refractory neuroblastoma remains a major therapeutic challenge. Apatinib is an oral multi-target tyrosine kinase inhibitor mainly targeting vascular endothelial growth factor receptor 2 (VEGFR-2). We evaluated the safety, efficacy, and pharmacokinetics of apatinib combined with irinotecan and temozolomide in patients with relapsed or refractory neuroblastoma.Methods: AIT-NB-01 is a multicentre, single-arm, phase 1/2 trial conducted across five centres in China. Patients aged ≥2 years with relapsed or refractory high-risk neuroblastoma were eligible for this study. In phase 1, apatinib (150, 300, or 450 mg/m2) combined with irinotecan (50 mg/m2 intravenously, days 1–5) and temozolomide (150 mg/m2 intravenously, days 1–5) was evaluated using a 3+3 design. In phase 2, patients received apatinib at the recommended phase 2 dose (RP2D) for up to eight cycles, followed by apatinib maintenance until disease progression or unacceptable toxicity. The primary endpoint were the maximum tolerated dose, RP2D and dose-limiting toxicity in phase 1, and best objective response rate (ORR) at the RP2D in phase 2. This completed trial has been registered with ClinicalTrials.gov (NCT05027386).Findings: Between September 2021 and September 2024, 111 patients were enrolled (23 in phase 1; 88 in phase 2). The RP2D of apatinib was 300 mg/m2. Among 96 patients eligible for efficacy at the RP2D, 53 achieved an objective response (ORR: 55%, 95% confidence interval [CI]: 45–65). At a median follow-up of 24·9 months (interquartile range: 16·5–32·9), the median progression–free survival (PFS) was 11·7 (95% CI 10·4–16·6) months. Patients who received apatinib maintenance therapy had significantly longer PFS (median: 16·6 vs. 10·6 months; hazard ratio: 0·61, 95% CI: 0·37–1·00; p=0·0478). Grade 3–4 adverse events occurred in 68 (61%) patients, of which the most common were leukopenia (27%), neutropenia (25%), and thrombocytopenia (20%). Two serious treatment-related adverse events and no treatment-related deaths were reported.Interpretation: Apatinib combined with irinotecan and temozolomide demonstrated promising efficacy with a manageable safety profile in patients with relapsed or refractory neuroblastoma. Oral apatinib maintenance therapy was associated with improved PFS. Further evaluation in randomised controlled trials is warranted.